AIM Therapeutics Inc.

Advanced immune modulation therapeutics

This company was founded in mid-2005 by BioQuest using a technology that was licensed from a major Canadian university. In early 2007, the company merged with Salpep Biotechnology Inc., founded by leading scientists from the University of Alberta and the University of Calgary. BioQuest has sole responsibility of managing the drug development programs for AIM Therapeutics and has successfully raised over $5 million of private capital to fund the development of their technologies.

Medical technologies:

• Neutropel: Three amino peptides derived from submandibular gland peptide-T (SGP-T); and
• Ep1.B: Anti-inflammatory peptide derived from Apolipoprotein E
• Indications: Asthma, spinal cord injury, peripheral arterial disease and diabetes

For more information, please visit the AIM Therapeutics web site at www.aimtherapeutics.com, or contact BioQuest Innovations.

 Cascade Therapeutics Inc.

This company was founded by BioQuest in October 2007. Cascade has three breakthrough technologies, and has synthesized and characterized a broad series of compounds for each of their intellectual properties.  BioQuest has sole responsibility of managing the drug development programs and intellectual property estate for Cascade Therapeutics.  Currently, Cascade is focused on the development of advancing their lead candidates for the treatment of epilepsy and obesity through pre-clinical development to be Phase I ready by Q2 and Q4 2009 respectively.

Medical technologies:

• Aryl-amid therapeutic series;
• 5-HT_2C agonist therapeutic series; and
• 5-HT_2A antagonist/GlyT1 inhibitor dual activity compound series
• Indications: Epilepsy, obesity, anxiety, pain, schizophrenia and sleep disorders.

For more information, please visit the Cascade Therapeutics web site at www.cascadetherapeutics.com, or contact BioQuest Innovations.

Envoy Pharmaceuticals Inc.

This company was founded in the Fall of 2007, and is focused on the development of medical technologies relating to antagonists and positive allosteric modulators (“PAM”) of the GLP-2 receptor for the treatment of gastrointestinal disorders and diabetes.  BioQuest has sole responsibility for the management of Envoy’s drug development program and intellectual property estate, and is currently focused on lead optimization in the GLP2 PAM series with the goal of nominating a lead candidate for pre-clinical development in the first half of 2008.

For more information about Envoy or any of its programs, please contact BioQuest Innovations.

Previous Clients

NeuroMedix Inc.

Innovative medicines for neuronal diseases

This company was founded by BioQuest using a technology that was licensed from a major US university in mid-2005. BioQuest raised $500,000 in seed funding for the initial stages of development and was instrumental in all phases of the company’s initial development, including the drug development program.

• Medical technology: Anti-neuroinflammatory small molecules
• Lead indication: Alzheimer’s disease

NeuroMedix was acquired by Transition Therapeutics in March 2007. For more information about NeuroMedix, please contact Transition Therapeutics at www.transitiontherapeutics.com.